A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)

Purpose

To determine if prostate cancer patients treated with proton therapy, as compared to IMRT, experience:

Improved quality of life

Reduced toxicity

Non-inferior or even superior cancer control

To determine if Hypofractionated proton therapy is non-inferior to standard fractionated proton therapy in patient-reported outcomes & physician-reported toxicity.

Criteria

Males 30-80 years old

With localized, non-metastatic adenocarcinoma of the prostate

Low-risk, intermediate-risk, or high-risk disease

With a life expectancy estimation of at least 10 years

No previous prostate cancer treatment except for ADT

Performance Status 0-2

You Cannot:            

Have cancer anywhere else

Have very low-risk or very high-risk prostate cancer

Have any prior prostate surgery, other than biopsy

Have had any prior pelvic radiation treatment

Details

The total duration of this study is up to 10 years. The study consists of 3 periods:

Pre-Radiation Treatment Period

Radiation Treatment Period- Daily Radiation treatments (Monday-Friday) & Weekly visits with the physician

Follow Up Period- At 3 month, 6 months, & yearly from end of radiation treatment

Interested in more information on this clinical research study?

Contact WK Cancer Center Clinical Research Department at 318-212-8671

Interested in more information? Contact Us:

Radiation Oncology Services

IRB: University of Florida
IRB Number:
Trial Type: NA
Sponsor: Patient Centered Outcomes University of Florida